Eder, Julia http://orcid.org/0000-0003-1330-804X
Pfeiffer, Lisa
Wichert, Sven P.
Keeser, Benjamin
Simon, Maria S.
Popovic, David
Glocker, Catherine
Brunoni, Andre R.
Schneider, Antonius
Gensichen, Jochen
Schmitt, Andrea
Musil, Richard
Falkai, Peter
,
Dreischulte, Tobias
Henningsen, Peter
Bühner, Markus
Biersack, Katharina
Brand, Constantin
Brisnik, Vita
Ebert, Christopher
Gökce, Feyza
Haas, Carolin
Kaupe, Lukas
Raub, Jonas
Reindl-Spanner, Philipp
Schillock, Hannah
Schönweger, Petra
von Schrottenberg, Victoria
Vukas, Jochen
Younesi, Puya
Jung-Sievers, Caroline
Krcmar, Helmut
Lukaschek, Karoline
Lochbühler, Kirsten
Pitschel-Walz, Gabriele
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (GRK 2621, GRK 2621, GRK 2621)
Ludwig-Maximilians-Universität München
Article History
Received: 26 April 2023
Accepted: 4 November 2023
First Online: 13 December 2023
Declarations
:
: JE, LP, SW, BK, M S–S, DP, CG, ARB, AS, JG, AS declare that they have no conflict of interest. RM has reveived financial research support from the EU (H2020 No. 754740), and served as PI in clinical trials from Abide Therapeutics, Böhringer Ingelheim, Emalex Biosciences, Lundbeck GmbH, Nuvelution TS Pharma Inc., Oryzon, Otsuka Pharmaceuticals and Therapix Biosciences. PF is a co-editor of the German (DGPPN) schizophrenia treatment guidelines and a co-author of the WFSBP schizophrenia treatment guidelines; he is on the advisory boards and receives speaker fees from Janssen, Lundbeck, Otsuka, Servier, and Richter.